BEAM-102
Sickle Cell Disease
PreclinicalActive
Key Facts
About Beam Therapeutics
Beam Therapeutics is a clinical-stage biotech leader in base editing, a next-generation gene editing technology designed for precise, single-base DNA corrections without double-strand breaks. The company's mission is to deliver durable, one-time cures for serious genetic diseases, with its lead program, BEAM-101 for sickle cell disease and beta-thalassemia, now in Phase 1/2 trials. Beam's strategy leverages a fully integrated platform spanning discovery, development, and in-house GMP manufacturing to build a broad pipeline and establish dominant intellectual property in the precision genetic medicine space.
View full company profileTherapeutic Areas
Other Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ANXV | Annexin Pharmaceuticals | Research |
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |
| CT-101 | Cetya Therapeutics | Pre-clinical |
| Endari (L-glutamine oral powder) | Emmaus Life Sciences | Approved |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Digital Model for Sickle Cell Disease | Koneksa Health | Development/Validation |
| ILX-002 | Illexcor Therapeutics | Pre-clinical |
| Epeleuton | Afimmune | Phase 2 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| CLY-124 | Cellarity | Phase 1 |
| AB1 | AkiraBio | Pre-clinical |